Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer.
But, as the statements read on mutual fund, past performance is no guarantee of future results. Which stock is the better pick for long-term investors now? Here's how AbbVie and Pfizer compare.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Aktie
25,77 €
0,14 %
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
